Inactivation of calpain I and calpain II by specificity-oriented tripeptidyl chloromethyl ketones.

No abstract is available for this paper.

• Publication year

  1986

• Venue

  Journal of Biochemistry (Tokyo)

• Publication date

  Unknown publication date

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1093/OXFORDJOURNALS.JBCHEM.A135457PMID 3007444
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Comparative specificity and kinetic studies on porcine calpain I and calpain II with naturally occurring peptides and synthetic fluorogenic substrates.

  1984cited by this paper
• Comparison of low and high calcium requiring forms of the calcium-activated neutral protease (CANP) from rabbit skeletal muscle.

  1984cited by this paper
• Large-scale purification of porcine calpain I and calpain II and comparison of proteolytic fragments of their subunits.

  1984cited by this paper
• Purification and characterization of calcium-dependent proteases from rat heart.

  1983cited by this paper
• Rabbit skeletal muscle calcium-dependent protease requiring millimolar CA2+. Purification, subunit structure, and Ca2+-dependent autoproteolysis.

  1982cited by this paper
• Comparison of low- and high-calcium-requiring forms of the calcium-activated protease with their autocatalytic breakdown products.

  1982cited by this paper
• Peptidyl diazomethyl ketones are specific inactivators of thiol proteinases.

  1981cited by this paper
• Inhibition of epoxide derivatives on chicken calcium-activated neutral protease (CANP) in vitro and in vivo.

  1980cited by this paper

• An update on the therapeutic potential of calpain inhibitors: a patent review

  2020cites this paper
• Calpains as a Target for Idiopathic Pulmonary Fibrosis?

  2016cites this paper
• Cathepsin B is a New Drug Target for Traumatic Brain Injury Therapeutics: Evidence for E64d as a Promising Lead Drug Candidate

  2015cites this paper
• Covalent Enzyme Inhibitors in Drug Design

  2015cites this paper
• Cysteine proteases as therapeutic targets: does selectivity matter? A systematic review of calpain and cathepsin inhibitors

  2015cites this paper
• Morelloflavone and its semisynthetic derivatives as potential novel inhibitors of cysteine and serine proteases

  2015cites this paper
• Calpain inhibitor design inspired by the natural inhibitor calpastatin

  2014cites this paper
• α-Amino-α'-halomethylketones: synthetic methodologies and pharmaceutical applications as serine and cysteine protease inhibitors.

  2013cites this paper
• Development of α-helical calpain probes by mimicking a natural protein-protein interaction.

  2012cites this paper
• Peptidyl alpha-ketoamides with nucleobases, methylpiperazine, and dimethylaminoalkyl substituents as calpain inhibitors.

  2010cites this paper
• The microtubule-targeting agent T0070907 induces proteasomal degradation of tubulin.

  2009cites this paper
• Natural polyprenylated benzophenones inhibiting cysteine and serine proteases.

  2009cites this paper
• A proteomic study of calpain-3 and its involvement in limb girdle muscular dystrophy type 2a.

  2009cites this paper
• Profiling of calpain activity with a series of FRET-based substrates.

  2009cites this paper
• CALPAIN: TRANSITIONING FROM THE USE OF THE PROTEASE CORE TO THE FULL-LENGTH ENZYME FOR THE DEVELOPMENT OF SPECIFIC SUBSTRATES AND INHIBITORS

  2008cites this paper
• Involvement of Chymotrypsin-Like Serine Proteases in Cell Death Processes

  2008cites this paper
• Exploration of orally available calpain inhibitors. Part 3: Dipeptidyl alpha-ketoamide derivatives containing pyridine moiety.

  2006cites this paper
• DESIGN, SYNTHESIS, AND EVALUATION OF CYSTEINE

  2005cites this paper
• Determination of peptide substrate specificity for mu-calpain by a peptide library-based approach: the importance of primed side interactions.

  2005cites this paper
• Coxsackievirus and adenovirus receptor (CAR) is modified and shed in membrane vesicles.

  2004cites this paper
• Activation of chymotrypsin-like serine protease(s) during apoptosis detected by affinity-labeling of the enzymatic center with fluoresceinated inhibitor.

  2002cites this paper
• Irreversible inhibitors of serine, cysteine, and threonine proteases.

  2002cites this paper
• Sequential Activation of Caspases and Serine Proteases (Serpases) During Apoptosis

  2002cites this paper
• Proteinase families and their inhibitors.

  2001cites this paper
• A survey of calpain inhibitors.

  2000cites this paper
• Cyclopropenone-containing cysteine proteinase inhibitors. Synthesis and enzyme inhibitory activities.

  1999cites this paper
• Calpain inhibitors as potential treatment for stroke and other neurodegenerative diseases: recent trends and developments

  1998cites this paper
• Development and therapeutic potential of calpain inhibitors.

  1997cites this paper
• Peptidyl aldehyde derivatives as potent and selective inhibitors of cathepsin L

  1995cites this paper
• A Neuroendocrine-specific Protein Localized to the Endoplasmic Reticulum by Distal Degradation (*)

  1995cites this paper
• Calpain Cleavage of the Cytoplasmic Domain of the Integrin β2 Subunit (*)

  1995cites this paper
• Calcium-binding proteins 1: EF-hands.

  1995cites this paper
• Calpains and calpastatin in human blood platelets.

  1995cites this paper
• Calcium-binding proteins. 1: EF-hands.

  1994cites this paper
• Specificity of calcium-activated neutral proteinase (CANP) inhibitors for human μCANP and mCANP

  1993cites this paper
• Comparative behaviour of calpain and cathepsin B toward peptidyl acyloxymethyl ketones, sulphonium methyl ketones and other potential inhibitors of cysteine proteinases.

  1992cites this paper
• Calcium-activated neutral protease (calpain) system: structure, function, and regulation.

  1991cites this paper
• Cysteinyl proteinases and their selective inactivation.

  1990cites this paper
• Purification of a novel type of calcium-activated neutral protease from rat brain. Possible involvement in production of the neuropeptide kyotorphin from calpastatin fragments.

  1990cites this paper
• Developing selective inhibitors of calpain.

  1990cites this paper
• Inhibitory effect of di- and tripeptidyl aldehydes on calpains and cathepsins.

  1990cites this paper
• Calpain and Calpastain in Platelets

  1990cites this paper
• Calpains (intracellular calcium-activated cysteine proteinases): structure-activity relationships and involvement in normal and abnormal cellular metabolism.

  1990cites this paper
• Peptide methyl ketones as reversible inhibitors of cysteine proteinases.

  1989cites this paper
• Calcium-dependent and phosphorylation-stimulated proteolysis of lipocortin I by an endogenous A431 cell membrane protease.

  1989cites this paper
• Identification and characterization of inhibitory sequences in four repeating domains of the endogenous inhibitor for calcium-dependent protease.

  1989cites this paper
• Identification of major autolytic cleavage sites in the regulatory subunit of vascular calpain II. A comparison of partial amino-terminal sequences to deduced sequence from complementary DNA.

  1989cites this paper
• Ubiquitin/ATP-Dependent Protease

  1988cites this paper
• The design of peptidyldiazomethane inhibitors to distinguish between the cysteine proteinases calpain II, cathepsin L and cathepsin B.

  1988cites this paper
• Trends in protease inhibition.

  1988cites this paper
• Analysis of structure-function relationship of pig calpastatin by expression of mutated cDNAs in Escherichia coli.

  1988cites this paper
• Synthesis of a new cell penetrating calpain inhibitor (calpeptin).

  1988cites this paper
• Chapter 2 Cysteine proteinases

  1987cites this paper
• The effects of autolysis on the structure of chicken calpain II.

  1987cites this paper
• Elucidation of calpain dependent phosphorylation of myosin light chain in human platelets.

  1987cites this paper